| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/03/2005 | US20050025826 Desolventizing a mixture of a bioactive peptide or salt thereof in an organic solvent, a biodegradable polymer, and hydroxynaphthoic acid or a salt; hydroxynaphthoate salt of a bioactive peptide |
| 02/03/2005 | US20050025819 Materials and methods for making improved micelle compositions |
| 02/03/2005 | US20050025807 Cured porous calcium phosphate material and uses thereof |
| 02/03/2005 | US20050025806 A silicone support of methylvinylsiloxane polymer including a fumed silca reinforcement filler; growth and/or reproduction-associated drug, derivative or analogue and carrier; each implant of insufficient size and/or payload for the predetermined threshold blood level of indicated drug; high-speed |
| 02/03/2005 | US20050025784 Compositions and methods for enhancing immune responses mediated by antigen-presenting cells |
| 02/03/2005 | US20050025776 Vascular inflammatory disorders, atherosclerosis, arteritis or reperfusion injury, autoimmune, nervous system and connective tissue disorders, rheumatoid arthritis, meningitis, multiple sclerosis, inflammatory bowel disorders, ulcerative colitis and Crohn's disease |
| 02/03/2005 | US20050025775 Contacting a sample with an isolated monoclonal antibody that binds to a substantially-pure coagulase-negative Staphylococcus epidermidis capsular polyssocharide adhesin antigen that binds to polymeric material, wherein said adhesin antigen inhibits binding to polymeric material |
| 02/03/2005 | US20050025770 Immunological methods for the treatment of gastrointestinal cancer |
| 02/03/2005 | US20050025769 Method of suppressing ongoing acute allograft rejection |
| 02/03/2005 | US20050025765 Antagonist is selected from an antioxidant or an inhibitor of a pro-inflammatory interleukin, TNF- alpha synthesis, membrane-bound TNF- alpha, a natural receptor of TNF- alpha, nitric oxide synthase, phospholipase A2, apoptosis, matrix metalloproteases, or p38 kinase |
| 02/03/2005 | US20050025760 Pemphigus monoclonal antibody |
| 02/03/2005 | US20050025759 administration of a platelet aggregation inhibitor containing Bacillus natto culture extract, nattokinase and Vitamin K2 as active ingredients; side effect reduction; effective food supplement, nutraceutical |
| 02/03/2005 | US20050025758 Method and compositions for treatment of insulin-dependant diabetes mellitus |
| 02/03/2005 | US20050025757 Oxygen carrier system, artificial oxygen carrier, and reducing agent |
| 02/03/2005 | US20050025751 Increased or reduced expression of tumor necrosis factors or interleukins; antiinflammatory agents; autoimmune diseases |
| 02/03/2005 | US20050025749 Grafting heart tissue; closure of heart defect |
| 02/03/2005 | US20050025748 Delivery of compounds with rehydrated blood cells |
| 02/03/2005 | US20050025746 Delivering an adeno-associated virus vector comprising a nucleotide sequence encoding glutamic acid decarboxylase to cells in specific areas of the brain; Parkinson's Disease, Alzheimer's Disease, Amyloid Lateral Sclerosis, and epilepsy |
| 02/03/2005 | US20050025744 Administration of humanized anti-IP-10 antibody in combination with beta-interferon 1a, beta-interferon 1b, glatiramer acetate, or humanized anti-VLA-4-antibody |
| 02/03/2005 | US20050025743 Administering peritoneal fibroblast cells prior to surgery to increase the expression levels of gamma interferon |
| 02/03/2005 | US20050025742 Interferon or a gene delivery system encoding the interferon and SYN3 as delivery enhancing agent; protein or gene therapy; transurethral intravesical administration to epithelial cells; superficial bladder cancer |
| 02/03/2005 | US20050025735 Ready to apply formulation containing enzyme that catalyzes acid generating reaction of hydantoin or dihydrouracil derivative; gentle, prolonged activity; uniformity |
| 02/03/2005 | US20050025734 Lactacystin, a peptidyl aldehyde, or a peptidyl epoxy ketone inhibits proteasomal activity; epidermal growth factor, a fibroblast growth factor, a platelet-derived growth factor, a transforming growth factor, a parathyroid hormone, etc for promoting skin tissue growth, an excipient |
| 02/03/2005 | US20050025723 Topical formulation containing melanocyte stimulating hormone and/or derivative in carrier |
| 02/03/2005 | US20050025722 Removing dental plaque with krill enzymes |
| 02/03/2005 | US20050025717 Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
| 02/03/2005 | US20050025716 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
| 02/03/2005 | US20050025715 Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders |
| 02/03/2005 | US20050025714 Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
| 02/03/2005 | US20050025713 Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
| 02/03/2005 | US20050025712 Transmucosal absorption through oral mucosa to systemic circulatory system; bioavailability, rapid onset; active ingredient, solvent and low molecular weight hydrocarbon propellant |
| 02/03/2005 | US20050025709 Immunological reagents for therapeutic use, for example, in radioimmunotherapy (RAIT), and diagnostic use, for example, in radioimmunodetection (RAID) and magnetic resonance imaging |
| 02/03/2005 | DE10332160A1 Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform A multiparticulate pharmaceutical form comprising mucoadhesively formulated peptide or protein active ingredients, and a process for preparing the drug form |
| 02/03/2005 | CA2533649A1 Combined treatments comprising synthetic peptide copolymers for preventing graft rejection |
| 02/03/2005 | CA2533551A1 Tissue adhesive sealant |
| 02/03/2005 | CA2533479A1 Peptide protein translation inhibitor and the use thereof for protein translation control |
| 02/03/2005 | CA2533421A1 Use of xmp-629 for the treatment of acne |
| 02/03/2005 | CA2533113A1 Soluble fragments of the sars-cov spike glycoprotein |
| 02/03/2005 | CA2532994A1 C5a receptor antagonists |
| 02/03/2005 | CA2532926A1 Combined use of immunostimulatory oligonucleotides and cytokines or radiation |
| 02/03/2005 | CA2532869A1 Novel peptidic conjugates for alopecia preventive and curative treatment |
| 02/03/2005 | CA2532679A1 Use of peptidic conjugates for preparing compositions for alopecia preventive and curative treatment |
| 02/03/2005 | CA2532370A1 Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 02/03/2005 | CA2532250A1 Compositions and methods for immunotherapy of cancer and infectious diseases |
| 02/03/2005 | CA2532035A1 Fugetactic proteins, compositions and methods of use |
| 02/03/2005 | CA2531491A1 Agonist polypeptide of receptor for zot and zonulin |
| 02/03/2005 | CA2531073A1 Human mast cell-expressed membrane protein |
| 02/03/2005 | CA2530284A1 Il-17 a/f heterologous polypeptides and therapeutic uses thereof |
| 02/03/2005 | CA2528458A1 A method of improving efficacy of biological response-modifying proteins and the exemplary muteins |
| 02/03/2005 | CA2526814A1 Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof |
| 02/03/2005 | CA2526240A1 7a5/prognostin and use thereof for the diagnostic and therapy of tumors |
| 02/03/2005 | CA2525829A1 Method of inhibiting atf/creb and cancer cell growth and pharmaceutical compositions for same |
| 02/03/2005 | CA2517600A1 Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections |
| 02/02/2005 | EP1502950A2 Method for purifying chemically modified RNA |
| 02/02/2005 | EP1502949A1 Antimicrobial polypeptide and utizliation thereof |
| 02/02/2005 | EP1502921A1 Recombinant mutated human factor VIII (FVIII) with improved stability |
| 02/02/2005 | EP1502920A2 Cell surface molecule mediating cell adhesion and signal transmission |
| 02/02/2005 | EP1502602A2 Methods for therapeutic vaccination |
| 02/02/2005 | EP1502601A1 Use of neurotoxin therapy for treatment of urinary retention |
| 02/02/2005 | EP1502600A1 Use of botulinum toxin for treating smooth muscle disorders |
| 02/02/2005 | EP1502599A1 Active antiangiogenic therapy |
| 02/02/2005 | EP1502116A2 Screening for peptides inhibiting pp1c binding to bcl-2, bcl-xl and bcl-w proteins |
| 02/02/2005 | EP1502109A2 Compositions and methods relating to endothelial cell signaling using the protease activated receptor (par1) |
| 02/02/2005 | EP1502020A2 Stackable low depth tray |
| 02/02/2005 | EP1501948A1 A dna enzyme to inhibit plasminogen activator inhibitor-1 |
| 02/02/2005 | EP1501941A1 Antisense modulation of jagged 2 expression |
| 02/02/2005 | EP1501936A2 Cytokine protein family |
| 02/02/2005 | EP1501931A2 Chimeric snrna molecules carrying antisense sequences against the splice junctions of the dystrophin gene and their therapeutic applications |
| 02/02/2005 | EP1501930A2 Oligomeric compounds for the modulation hif-1alpha expression |
| 02/02/2005 | EP1501925A2 Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis |
| 02/02/2005 | EP1501923A2 Pak5-related compositions and methods |
| 02/02/2005 | EP1501922A2 METHODS OF MODULATING HEME OXYGENASE−1 EXPRESSION AND TREATING HEME OXYGENASE−1 MEDIATED CONDITIONS |
| 02/02/2005 | EP1501870A2 Rsv proteins, antibodies, compositions, methods and uses |
| 02/02/2005 | EP1501868A1 Hexamers of receptors, members of the tnf receptor family, their use in therapy and pharmaceutical compositions comprising the same |
| 02/02/2005 | EP1501866A2 Apo-2 ligand variants and uses thereof |
| 02/02/2005 | EP1501864A1 Metallo proteinase inhibitory agent |
| 02/02/2005 | EP1501862A2 Novel analogues of glucose-dependent insulinotropic polypeptide |
| 02/02/2005 | EP1501861A1 Targeting proteins to deliver therapeutic or diagnostic reagents |
| 02/02/2005 | EP1501860A2 Modulation of heat-shock-protein-based immunotherapies |
| 02/02/2005 | EP1501857A2 Novel pancortin-pablo protein interactions and methods of use thereof |
| 02/02/2005 | EP1501855A2 Novel compositions and methods in cancer |
| 02/02/2005 | EP1501854A2 Antisense modulation of hmgi-c expression |
| 02/02/2005 | EP1501853A2 RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 02/02/2005 | EP1501852A2 Regeneration of endogenous myocardial tissue by induction of neovascularization |
| 02/02/2005 | EP1501605A1 Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency |
| 02/02/2005 | EP1501558A1 Resorbable pharmaceutical formulation for the continuous release of thrombin |
| 02/02/2005 | EP1501548A1 Chemically activated carboxypolysaccharides and uses |
| 02/02/2005 | EP1501547A1 Methods and conpositions for treating, preventing or delaying onset of a neoplasm |
| 02/02/2005 | EP1501540A1 T-cell epitodes in carboxypeptidase g2 |
| 02/02/2005 | EP1501539A1 Method for control of depression using c terminal growth hormone (gh) fragment |
| 02/02/2005 | EP1501538A2 Use of alpha-s2 casein precursor-derived peptides |
| 02/02/2005 | EP1501537A1 Mannose binding lectin and uses thereof |
| 02/02/2005 | EP1501535A1 Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents |
| 02/02/2005 | EP1501534A2 Desmopressin in an orodispersible dosage form |
| 02/02/2005 | EP1501533A2 Peptide inhibitors of protein kinase c ϝ for pain management |
| 02/02/2005 | EP1501532A2 Peptide inhibitors of protein kinase c |
| 02/02/2005 | EP1501530A2 Prostaglandin f2 alpha analogs in combination with antimicrobial for treating glaucoma |
| 02/02/2005 | EP1501489A1 Combination therapy for the treatment of cancer |
| 02/02/2005 | EP1501485A1 High drug load tablet |
| 02/02/2005 | EP1501482A1 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |